TheraRadar
← Back
Data updated: Jun 28, 2026

PHARMACO

Pharma

PHARMACO is a pharmaceutical company focused on Neurology, Immunology.

1976
Since
6
Drugs
-
Trials
0
New Drugs (2yr)

PHARMACO's Key Drugs

PHARMACO's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PHARMACO's Recent FDA Approvals

New NDA/BLA approvals for PHARMACO over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PHARMACO's Therapeutic Areas

PHARMACO's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 50%
1 drugs
Immunology 50%
1 drugs

PHARMACO's Top Competitors

PHARMACO's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

PHARMACO Pipeline Snapshot

Active clinical trials for PHARMACO across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling